Switch to:
More From Other Websites
Teva/Xenon Nerve Pain Candidate Fails in Phase II Study Jun 28 2017
World's largest generic drugmaker warns health-care industry faces 'huge disruption' Jun 28 2017
Teva Pharma CEO on health-care bill and disruption Jun 27 2017
This Biotech Crashed 28% Despite Positive Migraine Drug Tests Jun 27 2017
Valeant: Out of the Frying Pan, Into the Fire Jun 27 2017
UPDATED: Xenon and Teva say mid-stage nerve pain drug missed primary, secondary endpoints Jun 27 2017
Short Sellers Run for Cover From Major Pharma Jun 27 2017
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia... Jun 27 2017
iQ100 up over twenty percent this year Jun 26 2017
Valeant Pharma: A Debt Swap? Jun 26 2017
Allergan Continues to Focus on Acquisitions and Branded Unit Jun 26 2017
What You Don't Know About Generic Drugs, and How It Can Hurt You Jun 26 2017
These 3 Stocks Are Up Over 500% in the Last 3 Years Jun 25 2017
Facebook, Baidu, Coach And 5 Other Blue-Chip Stocks To Buy For Second-Half 2017 Jun 24 2017
Today's Research Reports on Stocks to Watch: Geron Corporation and Teva Pharmaceutical Jun 23 2017
Glaxo's (GSK) Shingles Candidate Phase III Data Positive Jun 22 2017
GSK wins $235 million from Teva in Coreg patent trial Jun 21 2017
Israeli credit card firm Isracard names outgoing Teva CFO as chairman Jun 21 2017
ETFs with exposure to Teva Pharmaceutical Industries Ltd. : June 20, 2017 Jun 20 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK